ERBB2 and breast neoplasm: These findings indicated a deregulation of the glutaminolysis pathway in basal-like tumors confirming previous reports that ER and HER2 negative breast tumors possess the highest glutamate to glutamine (Glu/Gln) ratios [41, 42].